Psychedelic drug

Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference

Retrieved on:

Thursday, March 28, 2024

Tel Aviv University, EST, Conference, Research, Good manufacturing practice, FRA, Health Canada, GMP, Ground substance, Safety, API, Good, MDMA, Therapy, Psychedelic drug, Drug development, Pharmaceutical industry

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference.

Key Points:

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference.
The 4th Annual Psychedelic Therapeutics and Drug Development Conference convenes renowned researchers and esteemed leaders from academia, industry, non-profit organizations, and government sectors to explore the challenges and opportunities inherent in the research and development of psychedelic therapies for various health conditions with significant unmet needs.
“We believe this conference serves as an excellent platform for us to engage with key stakeholders, exchange ideas, and drive innovation in the field of psychedelic therapeutics,” he added.
Optimi delegates will be available at the conference to host networking sessions for those seeking more information about the company's GMP and API drug products.

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

Retrieved on:

Tuesday, March 26, 2024

Tel Aviv University, Interdisciplinarity, Mental health, Research, FRA, Health Canada, Abstract, GMP, Quality, Ground substance, API, MDMA, Psychedelic drug, Pharmaceutical industry

In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.

Key Points:

In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.
Optimi has received the import permit from IPR-TLV and is in the process of obtaining its export permit from Health Canada.
Expected to commence in the summer of 2024 and conclude in late 2025, this study aligns with Optimi's commitment to supplying MDMA to international researchers advancing mental health and addictions research.
Commenting on the collaboration, Optimi CEO Bill Ciprick expressed his enthusiasm, stating, "Our agreement with IPR-TLV signifies an exciting entry into the Israeli psychedelics research market for Optimi.

ATMA CENA Psychedelic Healthcare Solutions Opens Psychedelic-Assisted Therapy Clinic in Calgary and Provides Update of its Clinic Network

Retrieved on:

Thursday, March 14, 2024

CALGARY, AB, March 14, 2024 /PRNewswire/ - ATMA CENA Psychedelic Healthcare Solutions (PHS) is a collaboration of ATMA Journey Centers Inc. ("ATMA"), Cena Life Inc ., and partners across Canada to advance and expand access to psychedelic-assisted therapy (PaT) through the establishment of a clinic network.

Key Points:

CALGARY, AB, March 14, 2024 /PRNewswire/ - ATMA CENA Psychedelic Healthcare Solutions (PHS) is a collaboration of ATMA Journey Centers Inc. ("ATMA"), Cena Life Inc ., and partners across Canada to advance and expand access to psychedelic-assisted therapy (PaT) through the establishment of a clinic network.
ATMA CENA PHS is pleased to announce commencement of the Calgary Clinic operations and its new location in Edmonton.
ATMA CENA Psychedelic Therapy Edmonton – 5555 Calgary Trail NW, Edmonton, AB
ATMA CENA Psychedelic Therapy Calgary – 742 – 42nd Ave SE, Calgary, AB
ATMA CENA Psychedelic Therapy Toronto – Woodbridge, Vaughan
Utilizing Alberta's Psychedelic Drug Treatment Service Standards and the College of Physicians and Surgeons of Alberta Accreditation Program as foundational principles, ATMA CENA clinics will aim to support the establishment of the necessary infrastructure that enables standardized care.
In the delivery of PaT across Canada, ATMA CENA PHS aims to support care that is safe, operationally consistent, efficient, effective, and regulation compliant.

MAPS Announces Celestial Plans for Its 38th Anniversary

Retrieved on:

Thursday, March 7, 2024

The event will also feature a Psychedelic Speakers Series curated by MAPS and a camping area for MAPS supporters.

Key Points:

The event will also feature a Psychedelic Speakers Series curated by MAPS and a camping area for MAPS supporters.
SAN JOSE, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- MAPS (Multidisciplinary Association for Psychedelic Studies) is excited to announce its collaboration with Texas Eclipse 2024 for its 38th anniversary celebration.
MAPS’ 38th anniversary, celebrating its founding on April 8, 1984, coincides with the last total solar eclipse that will be visible in the contiguous US for another 20 years.
The collaboration with Texas Eclipse will feature MAPS’ 38th Anniversary Psychedelic Speaker Series with MAPS Founder and President Rick Doblin, Ph.D., Allyson Grey & Alex Grey, Sutton King, Paul Stamets, and more!

Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Colorado

Retrieved on:

Tuesday, February 13, 2024

Psychedelic Science 2023, held this past June, boasted a record-breaking 22,000+ attendees -- 12,500 in-person and over 10,000 online through The Virtual Trip. Colorado Governor Jared Polis, Former Governor of Texas and US Secretary of Energy Rick Perry, Michael Pollan, Aaron Rodgers, and Melissa Etheridge were just a few of the speakers. The distinguished Dr. Roland Griffiths, professor of behavioral science and psychiatry and a pioneer in the advancement of psychedelic research, was also honored at the largest dinner event in the history of the Colorado Convention Center in one of his last public appearances before his death from cancer in October.

Key Points:

SAN JOSE, Calif. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies ( MAPS ) has announced that the Psychedelic Science 2025 Conference will convene in the city of Denver June 16–20, 2025, at the Colorado Convention Center.
This is the fifth edition of the Psychedelic Science conference series, hosted by MAPS.
Programming will explore the full spectrum of psychedelics, including science, medicine, policy, business, spirituality, and culture.
Psychedelic Science 2023, held this past June, boasted a record-breaking 22,000+ attendees -- 12,500 in-person and over 10,000 online through The Virtual Trip .

PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development

Retrieved on:

Friday, February 9, 2024

VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that it has entered into a consulting relationship with Red Light Holland Corp. (“Red Light”), (CSE: TRIP) to consult on the development of clinical-grade Psilocybin Drug Product extracted from Red Light Holland’s mushroom portfolio.

Key Points:

VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that it has entered into a consulting relationship with Red Light Holland Corp. (“Red Light”), (CSE: TRIP) to consult on the development of clinical-grade Psilocybin Drug Product extracted from Red Light Holland’s mushroom portfolio.
“As we have seen in the past number of months, the market for Psychedelic drug products is rapidly evolving.
PharmAla will also help Red Light with Regulatory Support and we are confident their knowledge, expertise and leadership, will help increase the efficiency of Red Light Holland in achieving our goal of supplying our psilocybin capsules to those in need, and creating positive change.”
Under the terms of the contract, PharmAla’s manufacturing experts have been retained by Red Light to consult and provide their expertise to Red Light in an all-cash consulting contract for one year, with the goal of developing GMP and regulatory documentation of Red Light’s Psilocybin capsule products.
The agreement also includes the provision that, upon completion of the Drug Product to specification, PharmAla and Red Light may enter into a sales agreement, where PharmAla would sell the products or provide them to its affiliates in global markets as Red Light’s exclusive sales agent.

PSYC’s CEO Provides Detailed Update on the State of the Company in Newly Released Podcast Recording

Retrieved on:

Friday, January 5, 2024

Frustration, OTC Markets Group, Psychedelic drug, Communication

The Company wishes to advise those who view and listen to the recording that some of the information, remarks, and opinions covered within it by Mr. Flores may be considered speculative and are covered under the Forward-Looking Disclaimer at the bottom of this press release.

Key Points:

The Company wishes to advise those who view and listen to the recording that some of the information, remarks, and opinions covered within it by Mr. Flores may be considered speculative and are covered under the Forward-Looking Disclaimer at the bottom of this press release.
“Given the extremely critical juncture that PSYC is in at present time, I felt it was important to provide our shareholders with as detailed, insightful, and transparent of an update as possible,” said Mr. Flores.
The podcast recording with Mr. Flores can be viewed through the following link: LINK TO PODCAST
The Company intends to provide shareholders with additional updates as more information becomes available.
Individuals interested in speaking directly with Mr. Flores may do so by emailing him at: [email protected]
Citations and Sources from Podcast:

PurMinds Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco

Retrieved on:

Thursday, December 14, 2023

Psilocybin, Qi, Psychedelic drug, DSM-IV codes, Pharmaceutical industry

This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

Key Points:

This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
PurMinds is set to meet with prospective partners and investors, discussing current and future strategic advancements.
This includes showcasing its small molecules (PUR400 series) and non-hallucinogenic Psychedelic molecule (PUR501) clinical programs, and proprietary formulation of botanical Psilocybin program (PUR101) for neurological disorders, as well as showcasing their licensed capacity to produce generic psychedelic compounds and proprietary formulations for worldwide distribution.
If you wish to book a meeting with PurMinds' management team, please contact us by email at [email protected] .

Unlocking Potential: Adeptus Partners to Highlight the Critical Intersection of Psychedelics and Sports at Wonderland Conference

Retrieved on:

Thursday, November 9, 2023

Well, Conference, Accounting, Partnership, Cannabis, Athlete, Energy drink, CFO, New Frontier, Psychedelic drug, Mental health, The Flaming Lips, IP, Sport, Longevity, Growth, Comprehensive, Nightclub

The launch of this effort coincides with a panel and workshop, being held at Wonderland Psychedelics Conference November 9th at 2:30 pm in Miami.

Key Points:

The launch of this effort coincides with a panel and workshop, being held at Wonderland Psychedelics Conference November 9th at 2:30 pm in Miami.
Adeptus Partners has built long-standing relationships with some of the world's top brands, athletes, influencers, and entertainers, with a roster of over 300 professional athletes.
For more information about the Adeptus Psychedelics & Cannabis Emerging Markets Practice and services, visit adeptuscpas.com or contact us .
If you are interested in attending the Wonderland Conference, visit wonderlandconference.com and use promotional code "ADEPTUS20" for 20% off your conference pass, then register for the workshop here .

The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day

Retrieved on:

Saturday, November 11, 2023

Courage, SAN, Psychedelic drug, Collection, Communication, MAPS, Research, Trauma, PTSD, Veteran

Psychedelic Science 2023: The Virtual Trip continues to add conference sessions, available on a sliding scale, to foster psychedelic knowledge.

Key Points:

Psychedelic Science 2023: The Virtual Trip continues to add conference sessions, available on a sliding scale, to foster psychedelic knowledge.
SAN JOSE, Calif., Nov. 11, 2023 (GLOBE NEWSWIRE) -- In honor of Veterans Day, the Multidisciplinary Association for Psychedelic Studies (MAPS) is highlighting a series of insightful discussions focused on critical Veterans’ issues from its breakthrough conference, hosted in June 2023 and now available online through Psychedelic Science 2023: The Virtual Trip .
This curated collection of sessions from the conference Veterans stage is part of MAPS’ ongoing commitment to supporting and advocating for Veterans living with PTSD.
We encourage everyone in our community to learn from and be inspired by the discussions from the Veterans stage at Psychedelic Science 2023."